Related Experiment Video
Updated: Mar 3, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
Daily Hemodialysis versus Standard Hemodialysis: TAC, TAD, Weekly eKt/V, std(Kt/V), and PCRn
Roula Galland1, Jules Traeger1, Ehsan Delawari1
1Association utilisation rein artificiel Lyon, France.
Insights
Daily hemodialysis (DHD) significantly improves urea clearance and reduces urea time-averaged deviation (TAD) compared to standard hemodialysis (SHD). This enhanced dialysis dose, with more frequent treatments, leads to better patient outcomes.
Area of Science:
- Nephrology
- Renal Replacement Therapy
- Dialysis Technology
Background:
- Standard hemodialysis (SHD) involves 4-5 hour sessions, three times weekly.
- Patients often undergo SHD for extended periods, averaging over 11 years.
- Switching to daily hemodialysis (DHD) offers a potential alternative treatment modality.
Purpose of the Study:
- To quantitatively compare the efficacy of standard hemodialysis (SHD) versus daily hemodialysis (DHD).
- To assess key dialysis parameters including urea clearance, protein catabolic rate, and overall dialysis adequacy.
Main Methods:
- Seven patients on SHD were switched to DHD (2-2.5 hours, six times weekly).
- Key parameters like time-averaged concentration (TAC), normalized protein catabolic rate (PCRn), and Kt/V were measured for both treatment types.
- Total weekly dialysis time remained consistent between SHD and DHD.
Main Results:
- Daily hemodialysis (DHD) significantly reduced urea TAC and urea time-averaged deviation (TAD).
- Normalized protein catabolic rate (PCRn) and weekly equilibrated Kt/V (eKt/V) increased with DHD.
- Equivalent normalized continuous standard clearance [std(Kt/V)] and equivalent renal urea clearance (eKRn) markedly improved with DHD.
Conclusions:
- Daily hemodialysis (DHD) offers superior urea clearance and reduced urea accumulation compared to SHD.
- The increased frequency of DHD, leading to a lower urea TAD, is a key factor in improved outcomes.
- DHD significantly enhances dialysis dose and may explain observed clinical improvements in patients.
Abstract:
Seven patients, mean age 42.57 ± 15.69 years (range 21 - 67 years), on standard hemodialysis (SHD), 4 - 5 hours, three times per week for 11.0 ± 6.63 years (range 1 - 18 years), were switched to daily hemodialysis (DHD), 2 - 2.5 hours, six times per week. For each type of treatment similar parameters were applied, and the total weekly time was the same. Mean duration of DHD was 15.4 ± 4.98 months (range 7 - 20 months). We report here our results of quantification in each method, including time-averaged concentration (TAC), normalized protein catabolic rate (PCRn), equilibrated Kt/V (eKt/V), equivalent normalized continuous standard clearance [std(Kt/V)], equivalent renal urea clearance (eKRn), and time-averaged deviation (TAD). With DHD, urea TAC was reduced from 19.09 ± 3.47 to 15.16 ± 3.21 mmol/L (p = 0.026), urea TAD diminished from 4.76 ± 1.04 to 2.52 ± 0.57 mmol/L (p = 0.000 53), PCRn increased from 1.11 ± 0.23 to 1.42 ± 0.24 g/kg/day (p = 0.001), weekly eKt/V increased from 4.11 ± 0.31 to 4.74 ± 0.43 (p = 0.000 25), std(Kt/V) rose from 2.17 ± 0.06 to 4.02 ± 0.25 (p = 0.0001), and eKRn increased from 12.96 ± 0.60 to 21.7 ± 3.09 mL/min (p = 0.000 45). On DHD the most important quantitative variation is the decrease of urea TAD (closer to that of a healthy kidney), due to the increased frequency of dialysis; std(Kt/V) practically doubled and represents 30% of that of normal renal function. These changes are probably the main explanation for the clinical improvements, but it is difficult to dissociate the effects of increased dialysis dose from the effects of decreased TAD.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
